Scarica l'app Stockscreener
28.28
0.86%
0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.04
Aprire:
$28.47
Volume 24 ore:
1.87M
Relative Volume:
1.37
Capitalizzazione di mercato:
$18.14B
Reddito:
$2.62B
Utile/perdita netta:
$966.70M
Rapporto P/E:
18.85
EPS:
1.5004
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+1.65%
1M Prestazione:
+18.72%
6M Prestazione:
+39.65%
1 anno Prestazione:
+6.80%
Intervallo 1D:
$28.28
$28.57
Intervallo di 1 settimana:
$27.84
$28.57
Portata 52W:
$17.23
$28.75
Genmab Adr Stock (GMAB) Company Profile
Confronta GMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
28.28 | 17.26B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-01 | Downgrade | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Downgrade | Citigroup | Neutral → Sell |
| 2023-12-06 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Aggiornamento | DNB Markets | Sell → Buy |
| 2023-10-18 | Iniziato | Exane BNP Paribas | Underperform |
| 2023-09-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Iniziato | BTIG Research | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-31 | Iniziato | UBS | Neutral |
| 2023-05-12 | Iniziato | Morgan Stanley | Underweight |
| 2022-12-20 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-14 | Iniziato | William Blair | Mkt Perform |
| 2022-11-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-05-02 | Iniziato | Cowen | Market Perform |
| 2022-03-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-12-01 | Iniziato | Berenberg | Sell |
| 2021-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-01-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Downgrade | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-06-25 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Iniziato | Credit Suisse | Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | Morgan Stanley | Overweight |
| 2019-08-12 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Genmab Adr Borsa (GMAB) Ultime notizie
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB - MarketBeat
Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighStill a Buy? - MarketBeat
Northern Trust Corp Raises Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P. - MarketBeat
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewswire Inc.
Graham Capital Management L.P. Acquires 16,035 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Orbis Allan Gray Ltd Has $111.82 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Synovus Financial Corp Takes $633,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Tema Etfs LLC Boosts Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World
IBD Rating Upgrades: MINISO Group Holding ADR Flashes Improved Technical Strength - inkl
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
IBD Rating Upgrades: HCA Healthcare Shows Improved Technical Strength - inkl
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World
What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - The Globe and Mail
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - The Globe and Mail
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Zacks Investment Research
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Genmab Adr Azioni (GMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.62%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):